Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gamida Cell Ltd (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel, GDA-201. Omnidibicel is an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia. GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.
Gamida Cell Ltd premium industry data and analytics
Products and Services
Products |
---|
Omidubicel - Hematologic Malignancies and Severe Aplastic Anemia |
GDA-201 - Non-Hodgkin Lymphoma |
NAM Technology Platform |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | The company received approval from the US Food and Drug Administration (FDA) for its Gamida Cell’s allogeneic cell therapy. |
2020 | Contracts/Agreements | In October, the company collaborated with Be The Match BioTherapies for omidubicel, Gamida Cell’s advanced cell therapy in Phase 3 clinical development. |
2019 | Contracts/Agreements | In January, the company and Be The Match BioTherapies collaborated to improve outcomes for patients undergoing allogeneic hematopoietic stem cell (bone marrow) transplantation. |
Competitor Comparison
Key Parameters | Gamida Cell Ltd | Fate Therapeutics Inc | MediPost Co Ltd | Dianthus Therapeutics Inc | Bellicum Pharmaceuticals Inc |
---|---|---|---|---|---|
Headquarters | Israel | United States of America | South Korea | United States of America | United States of America |
City | Jerusalem | San Diego | Seongnam | Cambridge | Houston |
State/Province | - | California | - | Massachusetts | Texas |
No. of Employees | 145 | 181 | 209 | 53 | 13 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Robert Blum | Chairman | Executive Board | 2018 | 56 |
Shawn Cline Tomasello | Chairman | Executive Board | 2019 | 64 |
Abigail L. Jenkins, M.S. | Chief Executive Officer; Director; President | Executive Board | 2022 | 47 |
Terry Coelho, M.B.A. | Chief Financial Officer | Senior Management | - | - |
Michele Korfin, R.Ph., M.B.A. | Chief-Commercial Officer; Chief Operating Officer | Senior Management | 2020 | 51 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer